Hexaminolevulinate

CHEMBL1201784 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
215.3 g/mol
LogP
1.1
Phase
4

This prodrug is used as a photosensitizing agent to improve the detection of bladder cancer during cystoscopy. After being instilled into the bladder, it is absorbed by cancer cells and converted to fluorescent compounds, causing them to glow pink-red under blue-violet light while normal tissue appears blue. This technique helps doctors visualize and biopsy suspicious lesions more accurately.

น้ำหนักโมเลกุล

215.2900 g/mol

LogP

1.10

TPSA

69.40 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

กลไกการออกฤทธิ์

Accumulates in target tissues and generates reactive oxygen species upon activation by specific wavelengths of light, causing localized cellular damage and destruction of pathological tissue.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Accumulates in target tissues and generates reactive oxygen species upon activation by specific wavelengths of light, causing localized cellular damage and destruction of pathological tissue.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCCCCCOC(=O)CCC(=O)CN

InChI

InChI=1S/C11H21NO3/c1-2-3-4-5-8-15-11(14)7-6-10(13)9-12/h2-9,12H2,1H3

Molecular Formula

C11H21NO3

HBD / HBA

1 / 4

พันธะที่หมุนได้

10

อะตอมหนัก

15

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

This prodrug is used as a photosensitizing agent to improve the detection of bladder cancer during cystoscopy. After being instilled into the bladder, it is absorbed by cancer cells and converted to fluorescent compounds, causing them to glow pink-red under blue-violet light while normal tissue appears blue. This technique helps doctors visualize and biopsy suspicious lesions more accurately.

Accumulates in target tissues and generates reactive oxygen species upon activation by specific wavelengths of light, causing localized cellular damage and destruction of pathological tissue.

Yes, Hexaminolevulinate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201784. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6433083. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.